Table 2 CTCs per cohort and by time point, including CTC immune checkpoint biomarker expression for baseline
From: Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer
| Â | mCRPC pre-ARSI | mCRPC post-ARSI | mHSPC starting ADT | Total |
|---|---|---|---|---|
EPCAM CTC Number per 7.5 mL whole blood (CellSearch) | ||||
Baseline CTCs | N = 10 | N = 10 | N = 10 | N = 30 |
 Mean (SD) | 29.4 (55.2) | 53.5(98.3) | 16.6 (23.9) | 33.2 (66.1) |
 Median (range) | 10.3 (0.3–181.0) | 5.1(0.8–291.3) | 3.1 (1.3–72.8) | 4.3 (0.3–291.3) |
  ≥ 5 CTCs | 5 (50%) | 5 (50%) | 4 (40%) | 14 (47%) |
Week 12 CTCs | N = 6 | N = 4 | N = 9 | N = 19 |
 Mean (SD) | 8.5 (16.0) | 1.3 (0.9) | 0.7 (0.8) | 3.3 (9.2) |
 Median (range) | 0.9 (0.0–40.5) | 1.0 (0.5–2.5) | 0.0 (0.0–2.5) | 0.8 (0.0–40.5) |
  ≥ 5 CTCs | 2 (33%) | 0 (0%) | 0 (0%) | 2 (10%) |
Disease progression CTCs | N = 7 | N = 6 | N = 2 | N = 15 |
 Mean (SD) | 62.6 (125.6) | 62.3 (94.0) | 0.3 (0.4) | 54.1 (101.9) |
 Median (range) | 20.8 (0.5–345.3) | 28.4 (1.0–244.3) | 0.3 (0.0–0.5) | 3.3 (0.0–345.3) |
  ≥ 5 CTCs | 4 (57%) | 3 (50%) | 0 (0%) | 7 (46%) |
CTC immune checkpoint biomarker expression at baseline | ||||
 PD-L1 Expression | ||||
   ≥ 1 CTC positive | 6 (60%) | 7 (70%) | 4 (40%) | 17 (57%) |
   ≥ 50% CTCs positive | 2 (20%) | 3 (30%) | 3 (30%) | 8 (27%) |
 PD-L2 expression | ||||
   ≥ 1 CTC positive | 4 (40%) | 2 (20%) | 4 (40%) | 10 (33%) |
   ≥ 50% CTCs positive | 2 (20%) | 2 (20%) | 3 (30%) | 7 (23%) |
 B7-H3 expression | ||||
   ≥ 1 CTC positive | 8 (80%) | 9 (90%) | 9 (90%) | 26 (87%) |
   ≥ 50% CTCs positive | 8 (80%) | 9 (90%) | 8 (80%) | 25 (83%) |
 CTLA-4 expression | ||||
   ≥ 1 CTC positive | 2 (20%) | 1 (10%) | 1 (10%) | 4 (13%) |
   ≥ 50% CTCs positive | 1 (10%) | 1 (10%) | 1 (10%) | 3 (10%) |